EVANSMED - Evans Medical Plc
Evans Medical Plc is a Nigeria-based company, active in the healthcare industry. The company is engaged in the manufacturing, research, and development of pharmaceutical products. Its portfolio of product includes Multivites, Cofta, Vanclox, Rapidflox, Amovin, and Ferbelan. Evans Medical Plc undertook a restructuring that saw the company metamorphose into four different companies, namely, Evans Medical Plc (which is primarily engaged in manufacturing, sales, and marketing of OTC-Products), Evans Nutraceutical Ventures Limited, CiplaEvans Nigeria Limited, and Evans Healthcare Nigeria Limited. Evans Medical Plc operates a network of 30 pharmacies in Nigeria.
|Last Trading Results||Growth & Valuation|
|Opening Price:||--||Earnings Per Share:||--|
|Day's Low Price:||--||Price/Earning Ratio:||--|
|Day's High Price:||--||Dividend Per Share:||--|
|Traded Volume:||0||Dividend Yield:||--|
|Number of Deals:||0||Shares Outstanding:||732.35m|
EVANSMED Stock Market Performance
The current share price of Evans Medical Plc (EVANSMED) is NGN 0.50. The EVANSMED stock closed its last trading day (Tuesday, July 4, 2017) at 0.50 NGN per share on the Nigerian Stock Exchange. The table below details the last 10 trading days of activity of Evans Medical Plc on the Nigerian Stock Exchange.
Profile of Evans Medical Plc
Evans Medical Plc operates in the Health Care sector. Unfortunately, we do not have information on the company's board of directors and/or key executives at this time.
|Factsheet of Evans Medical Plc|
Plot 6, Abimbola Way, Isolo, Lagos, Nigeria
EVANSMED Industrial Market Competitors
Evans Medical Plc, issuers of the EVANSMED stock on the Nigerian Stock Exchange, have a number of market competitors who are also engaged in the Health Care sector. The table below gives you an overview of the market standing of the top nine by year-to-date performance.
|Code||Name||Mkt. Cap.||L. Price||YearTD|
|MAYBAKER||May & Baker Nigeria||6.30b||3.65||+3.99%|
|GLAXOSMITH||Glaxo Smithkline Consumer||8.37b||7.00||+1.45%|
|NEIMETH||Neimeth International Pharma||3.80b||2.00||-10.3%|